|Podcasts|June 10, 2020

ASCRS 2020: Returning to baseline post-corneal collagen crosslinking for keratoconus

Julianne Matthews, MD, MPH, a resident at The Ohio State University, speaks with Ophthalmology Times'® David Hutton on the key highlights from her presentation "How Long Does It Take for Bcva, Kmax, and Pachymetry to Return to Baseline after Corneal Collagen Crosslinking for Keratoconus?," during the 2020 ASCRS virtual meeting.

See more ASCRS coverage here

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

ASCRS 2020: Returning to baseline post-corneal collagen crosslinking for keratoconus

Related Content

Frantz EyeCare LAL outcomes exceed national benchmarks in single-center cataract data

Emerging dry eye therapies and co-managing MGD: Ping Moore, OD

Why aren’t there enough ophthalmologists?

Personalizing dry eye treatment by addressing disease at its source

Root cause–based dry eye classification and the shift toward precision medicine

Latest CME

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

(COPE Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Embracing the Interventional Glaucoma Mindset: A Paradigm Shift in Contemporary Glaucoma Management

(CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies

(COPE Track) Emerging Therapeutic Advancements in Dry Eye Disease Management

(COPE Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

(CME Track) Cutting-Edge Care in Neovascular Retinal Disease: Expert Approaches to Selection and Interval Extension

(CME Track) Next-Generation Solutions for nAMD and DME: Bridging Evidence and Practice Gaps in Disease Management

Trending on Eye Care Network - Ophthalmology Times

EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease

EURETINA 2026: Predicting geographic atrophy progression with DARC

MOGENRY earns Japan priority review for inherited retinal dystrophies

Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease

EURETINA 2026: Gene therapy sessions to watch in Vienna